Clinical Trial Update: A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study of nivolumab (BMS-936558) in advanced or recurrent malignancies completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Metastatic Castration-resistant Prostrate Cancer, Renal Cell Carcinoma | Phase 1 | Status: COMPLETED | Results posted: 2016-04-15